Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Sing T, Sander O, Beerenwinkel N, Lengauer T
Los estudios clnicos han demostrado que semaglutide mejora significativamente el control glucmico en pacientes con diabetes tipo 2
While we still need more long-term data, the evidence available so far appears fairly reassuring
The analysis found that the high, medium, and low doses of tirzepatide approved for type 2 diabetes (15 mg, 10 mg, and 5 mg) were more effective in reducing A1C when compared against the respective high, medium, and low doses of subcutaneous semaglutide approved for type 2 diabetes (2 mg, 1 mg, and 0.5 mg)
.png)
If "stronger" means more familiar biology, a clearer bridge from an already-approved GLP-1 backbone, and a less radical product concept, CagriSema looks stronger
